Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arevo is a private Swedish agtech/biotech company developing arginine-based crop nutrition and plant establishment products for agriculture, horticulture, and forestry. Its core platform, Arginex, is designed to improve root development, nutrient uptake, nitrogen-use efficiency, and soil microbial health while reducing reliance on conventional mineral fertilizers. The company commercializes products in multiple delivery formats, including seed coatings, liquids, and granules, and markets solutions for crops such as soy, potato, corn, eucalyptus, and forestry seedlings. Arevo is built on research by founder Professor Torgny Näsholm on organic nitrogen uptake in plants and has positioned itself as a sustainable plant nutrition company rather than a human healthcare developer. The business appears to be commercially active and expanding internationally following financing rounds announced in 2024 and subsequent product-launch activity in late 2025.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arevo.